ClinicalTrials.gg
RecruitingNCT06266442Updated May 21, 2024

M. Avium WGS During Mav-PD Treatment

An observational study in Mycobacterium Avium, Mycobacterium Infections, Nontuberculous and Mycobacterium Infections, sponsored by University Health Network, Toronto. Recruiting at 1 site in Canada. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-05-21.

Sponsored by University Health Network, Toronto · Observational

How we know

From the registry’s dates

  • Started May 2024; still recruiting 2 years 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
40
Ages
18 Years and older
Sex
All
01

Study summary

This is a prospective observational study using whole genome sequencing (WGS) to investigate whether new strains (other than the initially identified strain(s)) of M. avium are responsible for persistently culture positive sputum during treatment (refractory disease), or the reversion to culture positive sputum after prior conversion to negative. The study will further investigate for differences between participants living in the Toronto/York region versus participants living elsewhere.

The primary goal of this prospective observational study is to understand why some patients with M. avium lung disease have persistent or recurrent M. avium in their sputum despite treatment. The aim is to understand whether it is usually due to treatment failure or new infection.

Read the detailed description

Mycobacterium Avium complex (MAC) are a subset of nontuberculous mycobacteria (NTM) that are typically found in the soil and water and can cause pulmonary lung disease. Treatment of MAC is challenging as it typically requires the use of three or more antibiotics for over a long period of time and the rate of eradication is suboptimal.

Mac-WGS is an observational study that aims to understand whether new strains of M. avium are responsible for persistently culture-positive sputum during treatment. Whole genome sequencing (WGS) will be performed on M. avium isolates from the sputum of patients with Mav-PD, over the duration of the study. Additionally, home environmental samples will be collected and sequenced to identify any home source of infection.

As an observational study, participants will receive routine standard of care treatment as per discretion of the physician. Standard of care includes monthly sputum submissions. The M. avium isolated from the sputum before treatment and every three months while on treatment (until such time that the sputum becomes culture-negative) will be analyzed by WGS. If sputum becomes culture-positive again, the isolated germ will also be analyzed by whole genome sequencing. It will be determined whether the identical strain of M. avium is always present or whether more than one strain is present which would suggest either multi-strain infection or the acquisition of new strains of M. avium while on treatment. Additionally, participant's home environmental samples (i.e. faucets and showerhead biofilms) will be cultured to determine whether M. avium can be recovered and if so, it will be analyzed with WGS to assess whether it is the same strain as in the participant's sputum.

02

Conditions studied

  • Mycobacterium Avium
  • Mycobacterium Infections, Nontuberculous
  • Mycobacterium Infections
  • Nontuberculous Mycobacterial Lung Disease
  • Respiratory Tract Diseases

Keywords

  • Nontuberculous mycobacterium
  • Whole genome sequencing
  • Mycobacterium avium
03

In context

Mycobacterium avium-intracellulare Infection

66 studies on the registry are indexed under Mycobacterium avium-intracellulare Infection; 8 are open to participants now.

This study's planned enrollment of 40 is below the median of 50 across 11 observational studies indexed under Mycobacterium avium-intracellulare Infection.

Browse Mycobacterium avium-intracellulare Infection studies →

Lead sponsor

University Health Network, Toronto is the lead sponsor of 1,441 studies on the registry; 298 are open to participants now.

Of its 17 completed or terminated interventional studies of FDA-regulated products, 3 (18%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Sampling method
Non-probability sample

Study population

Patients at the Toronto Western Hospital (TWH) Nontuberculous Mycobacterial (NTM) clinic who are to be initiated on therapy for Mav-PD.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 18 and older
  • Willing to provide and participate in study procedures
  • Residing continuously in Ontario during the past five years
  • Mav-PD, either initial or recurrent (previously treated patients will be eligible) five years
  • Meet American Thoracic Society (ATS) / Infectious Diseases Society of America (IDSA) NTM disease criteria for Mav-PD

Exclusion criteria

Exclusion Criteria:

  • Lack of an available pre-treatment M. avium isolate in the PHOL isolate bank
  • The inability to produce sputum either spontaneously or by induction with nebulized hypertonic saline
  • Cavitation >3 cm internal diameter
  • Known macrolide-resistant MAC infection
  • infection
  • Known diagnosis of cystic fibrosis
  • History of solid organ or hematological transplantation
  • Severe comorbid illness that is reasonably expected to limit survival to \<24 months
  • Residing in mid/north York region (King, Aurora, Newmarket, Whitechurch-Stouffville, East Gwillimbury or Georgina)
  • Having moved between regions (Toronto/southern York region vs non-Toronto/York region vs mid-northern York region) within the past 5 years
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
40 participants (estimated)
Patient registry
No
Biospecimen retention
Samples with dna

Interventions

  • OtherWhole genome sequencing testing

    Whole genome sequencing

06

What researchers measure

Primary outcomes

  1. Proportion of patients with persistent culture-positive sputum despite antimicrobial therapy

    Whole genome sequencing

    Time frame: 24 months

Secondary outcomes

  1. Whether patients with Mav-PD have evidence of polyclonal infection as demonstrated by the presence of >1 strain of M. avium in the pre-treatment sputum or a sputum sample during treatment

    Whole genome sequencing

    Time frame: 24 months

  2. Whether there is a source of infection from the home water environment

    M. avium strains from sputum and home water source samples will determined through WGS analysis.

    Time frame: 24 months

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started May 2024 (actual). Primary completion is estimated for Sep 2026, 28 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 27, 2023
First posted
Feb 20, 2024
StartActual
May 13, 2024
Primary completionEst.
Sep 2026
CompletionEst.
Sep 2026
Last update
May 21, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 21, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06266442
Collaborators
Western University, Canada, Public Health Ontario Laboratory, Canada
Responsible party
Theodore (Ted) Marras (Director, Toronto Western Hospital / University Health Network Nontuberculous Mycobacterial Disease Program, Principal Investigator, Associate Professor, University Health Network, Toronto) — Principal investigator
First posted
Feb 20, 2024
Start date
May 13, 2024
Primary completion
Sep 2026 (estimated)
Completion
Sep 2026 (estimated)
Last update
May 21, 2024

Study contacts

Theodore Marras, MD
Contact
ted.marras@uhn.ca
416-603-5767
Matty Mehrabi, BSc, M.Ed
Contact
matty.mehrabi@uhn.ca
416-603-5726
Theodore Marras, MD
principal investigator · UHN

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion